Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
06/02/2024 16:38
Feb 6 (Reuters) - Crossject SA 74C.F :
* CROSSJECT PROVIDES STRATEGIC UPDATE ON PRIORITIES FOR 2024
* CONTRACT OF UP TO $155 MILLION WITH BARDA FOR U.S.
STOCKPILING
CONTINUES TO ADVANCE
* IN 2024, CROSSJECT WILL ESPECIALLY FOCUS ON REGULATORY
APPROVALS
FOR ZEPIZURE AND ACCELERATING MARKET ACCESS EFFORTS IN UNITED
STATES
Source text for Eikon: ID:nGNX1GhDtL
Further company coverage: 74C.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure